Fabry disease in children: agalsidase-beta enzyme replacement therapy


  • We have no conflicts of interest to declare.

Corresponding author:

Line Borgwardt,

Department of Clinical Genetics,

Copenhagen University Hospital,

Rigshospitalet, Copenhagen 2100, Denmark.

Tel.: +45-25229158;

fax: +45-35454072;

e-mail: Line.gutte.borgwardt@rh.regionh.dk


Fabry disease is a rare, multiorgan disease. The most serious complications involve the kidney, brain and heart. This study aims to assess the effect of enzyme replacement therapy (ERT) using agalsidase-beta in children with Fabry disease. We carried out a nationwide, descriptive and observational retrospective cohort study of 10 children (9–16 years at baseline), who underwent regular systematic investigations for 1–8 years after initiation of ERT with agalsidase-beta (Fabryzyme®, Genzyme). Ophthalmological, echocardiographic abnormalities and hypohidrosis were found at baseline and during the follow-up period. Serious kidney, heart or brain involvement had not developed at the last follow-up examination. For the majority of the patients improvements were found concerning headache, acroparaesthesias and gastrointestinal pain during the follow-up period. The level of energy and physical activity also increased. Treatment with agalsidase-beta was associated with a reduction of neuropathic and abdominal pain and headache. Although all aspects of the Fabry pain phenotype cannot be treated with ERT, the observed effects were clinically significant in the lives of the majority of Fabry children and together with the absence of serious Fabry manifestations at last follow-up, we argue that early initiation of ERT may be considered.